ZK1098.4 Antibody

What is ZK1098.4 and what is known about its function in C. elegans?

ZK1098.4 is a protein in Caenorhabditis elegans identified by its UniProt accession number P34604 . While the complete functional characterization remains an active area of research, genomic studies indicate it may be involved in developmental processes. The protein has been studied in the context of whole genome RNAi knockdown screens, suggesting potential roles in various cellular pathways .

Methodological approach to functional characterization:

• Conduct phenotypic analysis following RNAi-mediated gene silencing

• Perform co-immunoprecipitation experiments to identify interaction partners

• Use fluorescent-tagged constructs to determine subcellular localization

• Implement CRISPR/Cas9 gene editing to generate knockout models

What applications is the ZK1098.4 antibody validated for?

The ZK1098.4 antibody has been validated for multiple research applications:

For research requiring high specificity, the antibody has been affinity-purified against the immunogen (recombinant Caenorhabditis elegans ZK1098.4 protein) .

What are the optimal storage conditions for ZK1098.4 antibody?

To maintain antibody activity and prevent degradation:

• Store at -20°C or -80°C for long-term preservation

• Avoid repeated freeze-thaw cycles, which can lead to protein denaturation and loss of activity

• If frequent use is necessary, prepare working aliquots to minimize freeze-thaw events

• The antibody is supplied in a storage buffer containing 50% glycerol, 0.01M PBS (pH 7.4), and 0.03% Proclin 300 as a preservative

• For short-term storage (1-2 weeks), the antibody can be kept at 4°C in the dark

Research has shown that antibodies stored under optimal conditions maintain >95% of their activity for at least 12 months.

How is the specificity of ZK1098.4 antibody verified?

Verification of antibody specificity involves multiple complementary approaches:

• Immunoblotting against recombinant protein: Confirming single band at the expected molecular weight

• Peptide competition assays: Pre-incubation with immunizing peptide should abolish specific signal

• RNAi knockdown validation: Signal reduction following ZK1098.4 knockdown

• Testing in knockout models: Absence of signal in ZK1098.4 null mutants

• Cross-reactivity analysis: Testing against closely related proteins such as ZK1098.6 and ZK1098.10

For researchers studying protein complexes, validation should include appropriate controls similar to those used in JLP/Max interaction studies, where specific antibodies against tags and leucine zipper domains were employed to verify protein interactions .

What is the recommended protocol for using ZK1098.4 antibody in Western blotting?

Optimized Western Blot Protocol for ZK1098.4 Antibody:

• Sample preparation:

  • Extract total protein from C. elegans using buffer S (250 mM Tris·HCl, pH 7.5, 137 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 0.5% sodium deoxycholate) with protease inhibitors (1 mM PMSF, 2 μg/ml pepstatin, 2 μg/ml leupeptin, 1.9 μg/ml aprotinin)

  • Heat samples at 95°C for 5 minutes in reducing sample buffer

• Gel electrophoresis:

  • Load 20-50 μg of protein per lane on 10-12% SDS-PAGE gels

  • Include positive control (recombinant ZK1098.4 protein)

• Transfer:

  • Transfer to PVDF membrane at 100V for 1 hour (or 30V overnight)

  • Verify transfer with reversible protein stain

• Blocking:

  • Block with 5% non-fat dry milk in TBST for 1 hour at room temperature

• Primary antibody incubation:

  • Dilute ZK1098.4 antibody 1:1000 in blocking solution

  • Incubate overnight at 4°C with gentle agitation

• Washing:

  • Wash 3 × 10 minutes with TBST

• Secondary antibody:

  • Use anti-rabbit HRP-conjugated antibody (1:5000)

  • Incubate for 1 hour at room temperature

• Detection:

  • Develop using enhanced chemiluminescence

  • Expect a band at approximately the predicted molecular weight for ZK1098.4

How can ZK1098.4 antibody be used in C. elegans RNAi knockdown studies?

ZK1098.4 antibody serves as a critical validation tool in RNAi knockdown experiments, enabling quantitative assessment of knockdown efficiency.

Integrated Methodology:

• RNAi knockdown implementation:

  • Use feeding RNAi with ZK1098.4-specific dsRNA-expressing bacteria

  • Include vector-only control and positive control knockdowns

  • Synchronize worm populations using standard hypochlorite treatment

• Protein extraction and quantification:

  • Extract proteins from equal numbers of worms (typically 50-100)

  • Quantify total protein using Bradford or BCA assay

  • Normalize loading based on total protein or housekeeping proteins

• Western blot validation:

  • Perform Western blot using optimized protocol (see question 1.5)

  • Include GAPDH or actin antibody as loading control

  • Quantify band intensity using appropriate imaging software

• Phenotypic assessment:

  • Document phenotypes using standardized scoring systems

  • Correlate phenotype severity with knockdown efficiency

  • Similar to approaches used in genome-wide RNAi screens that identified ZK1098.4 and related genes

This methodology has been validated in studies examining the effects of whole genome knockdown in C. elegans models for various conditions, including those studying alpha-1 antitrypsin deficiency .

What are the known protein interactions of ZK1098.4 in C. elegans?

While specific interaction partners of ZK1098.4 are still being characterized, methodological approaches for identifying protein interactions can be adapted from related studies:

Experimental Approaches for Interaction Discovery:

• Co-immunoprecipitation with ZK1098.4 antibody:

  • Prepare C. elegans lysates under non-denaturing conditions

  • Immunoprecipitate using ZK1098.4 antibody

  • Identify co-precipitating proteins using mass spectrometry

  • Similar to approaches used for JLP-Max interactions, which utilized specific antibodies against protein domains

• Yeast two-hybrid screening:

  • Use ZK1098.4 as bait against C. elegans cDNA library

  • Validate positive interactions with co-IP and in vivo assays

• Proximity labeling approaches:

  • Generate transgenic worms expressing ZK1098.4-BioID fusion

  • Identify proximal proteins through streptavidin pulldown and MS analysis

• Computational prediction:

  • Apply probabilistic latent factor models similar to those described for drug-target interaction prediction

  • Validate highest-confidence predictions experimentally

Preliminary data suggests ZK1098.4 may interact with proteins involved in developmental pathways, but comprehensive interaction mapping remains to be completed.

How does ZK1098.4 compare to other members of its protein family (e.g., ZK1098.6, ZK1098.10)?

ZK1098.4 belongs to a family of related proteins in C. elegans that includes ZK1098.6 and ZK1098.10. Comprehensive comparison requires multiple analytical approaches:

Comparative Analysis Framework:

• Sequence homology analysis:

  • Perform multiple sequence alignment using CLUSTAL Omega

  • Identify conserved domains and motifs

  • ZK1098.10 shows extensive homology with the C-terminal domain of the JLP scaffolding protein, suggesting potential functional similarities

• Structural prediction:

  • Generate structural models using AlphaFold or similar tools

  • Compare predicted functional sites

• Expression pattern comparison:

  • Use antibodies against each family member to determine tissue-specific expression

  • Create transgenic reporter lines for each gene

• Functional redundancy assessment:

  • Generate single and combined knockouts

  • Compare phenotypes across family members

  • Attempt rescue experiments across family members

The structural and functional relationships between these family members may provide insights into their evolutionary conservation and specialized roles.

What are the recommended troubleshooting approaches for non-specific binding with ZK1098.4 antibody?

Non-specific binding is a common challenge when working with antibodies in C. elegans research. Systematic troubleshooting approaches include:

Hierarchical Optimization Strategy:

• Blocking optimization:

  • Test alternative blocking agents (BSA, casein, commercial blocking solutions)

  • Increase blocking time from 1 hour to overnight

  • Add 0.1-0.5% Tween-20 to reduce hydrophobic interactions

• Antibody dilution optimization:

  • Perform titration series (1:500 to 1:5000)

  • Determine optimal signal-to-noise ratio

• Washing stringency adjustment:

  • Increase salt concentration in wash buffer (150mM to 500mM NaCl)

  • Add detergents (Tween-20, Triton X-100, NP-40) at varying concentrations

  • Extend washing times and increase number of washes

• Pre-adsorption protocol:

  • Incubate antibody with acetone powder from knockout or RNAi-treated worms

  • Remove antibodies binding to non-specific epitopes

• Secondary antibody optimization:

  • Test alternatives from different manufacturers

  • Use highly cross-adsorbed secondary antibodies

These approaches have been effective in optimizing antibody specificity in similar experimental systems, such as those used for determining protein interactions in JLP studies .

How can ZK1098.4 antibody be used in studies of protein localization in C. elegans?

Determining the subcellular and tissue localization of ZK1098.4 requires integration of multiple complementary approaches:

Integrated Localization Methodology:

• Whole-mount immunohistochemistry:

  • Fix worms with 4% paraformaldehyde (preferred) or Bouin's fixative

  • Permeabilize cuticle through freeze-crack method or collagenase treatment

  • Block with 10% normal goat serum and 1% BSA

  • Apply ZK1098.4 antibody (1:100 to 1:500 dilution)

  • Use fluorescence-conjugated secondary antibodies

  • Counterstain with DAPI for nuclear visualization

• Subcellular fractionation validation:

  • Separate nuclear, cytoplasmic, and membrane fractions

  • Perform Western blotting with ZK1098.4 antibody

  • Include markers for each fraction (e.g., histone H3 for nuclear, GAPDH for cytoplasmic)

• Correlation with transgenic fluorescent reporters:

  • Generate transgenic worms expressing ZK1098.4::GFP fusion

  • Compare antibody staining pattern with GFP signal

  • Similar approaches have been used for studying protein localization in MAP kinase pathways

• Colocalization studies:

  • Perform double-labeling with ZK1098.4 antibody and markers for specific organelles

  • Quantify colocalization using Pearson's correlation coefficient

  • Validate with super-resolution microscopy for ambiguous results

This methodology builds upon approaches used in activity-based protein profiling studies in C. elegans, which have successfully identified protein localization in complex proteomes .

How should controls be designed for ZK1098.4 antibody experiments?

Robust experimental design requires comprehensive controls to ensure validity and reproducibility:

Control Framework for ZK1098.4 Antibody Experiments:

• Positive controls:

  • Recombinant ZK1098.4 protein at known concentrations

  • Wild-type C. elegans lysate from developmental stages with known expression

• Negative controls:

  • ZK1098.4 knockout or RNAi-treated worm lysates

  • Pre-immune serum in place of primary antibody

  • Similar to controls used in studies of other proteins like JLP

• Specificity controls:

  • Peptide competition assay using immunizing peptide

  • Testing in related nematode species (cross-reactivity assessment)

  • Western blot against recombinant related proteins (ZK1098.6, ZK1098.10)

• Technical controls:

  • Loading controls (actin, tubulin, or GAPDH antibodies)

  • Secondary antibody-only control

  • Isotype control antibody at equivalent concentration

Implementation of these controls helps distinguish specific signals from artifacts and enables quantitative assessment of antibody performance across experiments.

What considerations are important when using ZK1098.4 antibody in quantitative analyses?

Quantitative applications require additional methodological considerations:

Quantitative Analysis Protocol:

• Standard curve establishment:

  • Use purified recombinant ZK1098.4 protein at 5-7 concentrations

  • Generate standard curves for each experimental batch

  • Determine linear range of detection

• Sample normalization strategies:

  • Normalize to total protein (determined by BCA or Bradford assay)

  • Use multiple housekeeping proteins as reference (GAPDH, actin, tubulin)

  • Include spike-in standards for absolute quantification

• Technical replication:

  • Perform minimum of three technical replicates

  • Calculate coefficient of variation (<15% is acceptable)

• Image acquisition optimization:

  • For Western blots, ensure exposure is within linear range

  • For immunofluorescence, standardize acquisition parameters

  • Use calibration standards for fluorescence microscopy

• Statistical analysis:

  • Determine appropriate statistical tests based on data distribution

  • Account for multiple comparisons when necessary

  • Report effect sizes alongside p-values

These methodological considerations align with best practices in antibody-based quantitation used in studies of complex proteomes and protein interactions .

How can epitope mapping be performed for ZK1098.4 antibody?

Understanding the specific epitope(s) recognized by the ZK1098.4 antibody is crucial for interpretation of experimental results:

Epitope Mapping Methodology:

• Peptide array analysis:

  • Synthesize overlapping peptides (15-20 amino acids) spanning ZK1098.4 sequence

  • Spot peptides on cellulose membrane

  • Probe with ZK1098.4 antibody

  • Identify reactive peptides through chemiluminescence

• Truncation mutant analysis:

  • Generate series of N- and C-terminal truncations of ZK1098.4

  • Express as recombinant proteins

  • Test antibody reactivity by Western blot

  • Similar to approaches used for mapping protein interaction domains

• Alanine scanning mutagenesis:

  • Introduce sequential alanine substitutions in identified peptide region

  • Test effect on antibody binding

  • Identify critical residues for epitope recognition

• Hydrogen-deuterium exchange mass spectrometry:

  • Compare H/D exchange patterns of ZK1098.4 alone versus antibody-bound

  • Identify regions protected from exchange upon antibody binding

This multi-faceted approach provides comprehensive characterization of antibody-epitope interactions, enabling better experimental design and interpretation.

How can ZK1098.4 antibody be used in high-throughput screening assays?

Adaptation of ZK1098.4 antibody for high-throughput applications requires optimization of several parameters:

High-Throughput Implementation Strategy:

• ELISA-based screening:

  • Develop sandwich ELISA with capture and detection antibodies

  • Optimize antibody concentrations and incubation times

  • Miniaturize to 384-well format

  • Include standard curves on each plate

  • Similar principles to those used in antigenic lateral flow immunoassays

• Automated Western blot analysis:

  • Implement capillary-based immunoassay systems

  • Optimize antibody concentration for reduced consumption

  • Develop standardized analysis parameters

• High-content imaging:

  • Optimize immunofluorescence protocol for automated microscopy

  • Develop image analysis algorithms for ZK1098.4 detection

  • Create machine learning classifiers for phenotype identification

• Multiplexed detection systems:

  • Conjugate ZK1098.4 antibody with unique fluorophores or barcodes

  • Combine with antibodies against other proteins of interest

  • Develop analysis pipelines for deconvolution of signals

These approaches build upon methodologies developed for other antibody-based high-throughput assays, such as those used in lateral flow immunoassays for foot-and-mouth disease virus detection .

What are the considerations for using ZK1098.4 antibody in developmental studies of C. elegans?

Developmental studies present unique challenges and opportunities for antibody applications:

Developmental Study Framework:

• Stage-specific expression analysis:

  • Synchronize worm populations at key developmental stages

  • Extract proteins from equal numbers of worms per stage

  • Perform Western blot analysis with ZK1098.4 antibody

  • Quantify relative expression across development

• Tissue-specific localization during development:

  • Perform whole-mount immunofluorescence at different stages

  • Counterstain with tissue-specific markers

  • Document changes in expression pattern

  • Similar approaches used in whole-genome knockdown studies

• Functional perturbation strategies:

  • Generate temperature-sensitive or developmentally regulated RNAi

  • Monitor ZK1098.4 levels during critical developmental windows

  • Correlate protein levels with phenotypic outcomes

• Integration with transcriptomic data:

  • Compare protein expression patterns with mRNA expression data

  • Identify potential post-transcriptional regulation

  • Analyze correlation between protein expression and phenotype

This integrated approach provides insights into the developmental roles of ZK1098.4, building upon methodologies used in large-scale genomic studies in C. elegans .

How can cross-reactivity between ZK1098.4 antibody and human proteins be assessed?

For researchers considering translational applications or working with multiple model systems:

Cross-Reactivity Assessment Protocol:

• In silico analysis:

  • Perform BLAST searches of ZK1098.4 epitope against human proteome

  • Identify proteins with significant sequence similarity

  • Predict potential cross-reactive epitopes

• Western blot screening:

  • Test ZK1098.4 antibody against human cell line lysates

  • Include C. elegans lysate as positive control

  • Document any cross-reactive bands

• Immunoprecipitation-mass spectrometry:

  • Perform IP using ZK1098.4 antibody on human samples

  • Identify pulled-down proteins by mass spectrometry

  • Similar approaches to those used in activity-based protein profiling

• Validation of identified cross-reactants:

  • Express recombinant human proteins identified in steps 1-3

  • Test direct binding of ZK1098.4 antibody

  • Determine binding affinity for cross-reactive proteins

Understanding potential cross-reactivity is crucial for experimental design and interpretation, particularly in comparative studies between model organisms and humans.

What are the best practices for validating new batches of ZK1098.4 antibody?

Batch-to-batch variation is a significant concern in antibody research. A systematic validation approach includes:

Batch Validation Protocol:

• Side-by-side comparison:

  • Run Western blots with old and new batches on identical samples

  • Compare band intensity, specificity, and background

  • Calculate correlation coefficient between signal intensities

• Titration curve analysis:

  • Generate antibody dilution series (1:100 to 1:10,000)

  • Compare EC50 values between batches

  • Document any shifts in optimal working concentration

• Epitope recognition verification:

  • Test reactivity against epitope-containing peptide

  • Perform peptide competition assay

  • Compare inhibition curves between batches

• Functional validation:

  • Perform immunoprecipitation with both batches

  • Compare pull-down efficiency of known interaction partners

  • Similar to approaches used for validating interaction partners in protein studies

Implementation of these validation procedures ensures experimental continuity and reproducibility across studies.

How can ZK1098.4 antibody be used in chromatin immunoprecipitation studies?

For researchers investigating potential DNA-binding or chromatin-associated functions:

ChIP Protocol Optimization:

• Cross-linking optimization:

  • Test formaldehyde concentrations (0.5-2%)

  • Optimize cross-linking times (5-20 minutes)

  • Include native ChIP (no cross-linking) as alternative approach

• Chromatin fragmentation:

  • Optimize sonication parameters for C. elegans samples

  • Target fragment size of 200-500 bp

  • Verify fragmentation by agarose gel electrophoresis

• Immunoprecipitation conditions:

  • Test different amounts of ZK1098.4 antibody (2-10 μg)

  • Optimize bead type and quantity

  • Include appropriate controls (IgG, input, non-specific antibody)

  • Similar to immunoprecipitation approaches used in protein interaction studies

• ChIP-qPCR validation:

  • Design primers for candidate target regions

  • Include positive control regions (if known)

  • Calculate enrichment relative to input and IgG control

• Data analysis considerations:

  • For ChIP-seq, use appropriate peak-calling algorithms

  • Compare binding sites with known regulatory elements

  • Integrate with transcriptomic data for functional interpretation

These methodological considerations address the specific challenges of ChIP applications in C. elegans, building upon established protocols for protein-DNA interaction studies.

How should researchers address potential degradation of ZK1098.4 during protein extraction?

Protein degradation can significantly impact experimental outcomes. A comprehensive strategy includes:

Degradation Prevention Protocol:

• Optimized extraction buffer:

  • Include multiple protease inhibitors (PMSF, leupeptin, pepstatin, aprotinin)

  • Add phosphatase inhibitors if phosphorylation status is relevant

  • Maintain cold temperature throughout extraction

• Extraction method comparison:

  • Test different lysis methods (sonication, homogenization, freeze-thaw)

  • Compare protein integrity by Western blot

  • Identify method minimizing degradation

• Time-course stability analysis:

  • Extract protein using optimized method

  • Aliquot and store at different temperatures (-80°C, -20°C, 4°C)

  • Test aliquots at different time points (0h, 24h, 72h, 1 week)

  • Determine optimal storage conditions

• Sample preparation optimization:

  • Test different reducing agents (β-mercaptoethanol vs. DTT)

  • Compare denaturation temperatures (37°C, 55°C, 95°C)

  • Optimize sample buffer composition

These approaches are based on established protocols for working with labile proteins in C. elegans, similar to those used in activity-based protein profiling studies .

What are the key considerations for using ZK1098.4 antibody in different C. elegans tissue types?

Tissue-specific applications require tailored approaches:

Tissue-Specific Optimization Framework:

• Fixation protocol optimization:

  • Compare fixatives (paraformaldehyde, methanol, Bouin's)

  • Optimize fixation times for different tissues

  • Test antigen retrieval methods if needed

• Permeabilization strategies:

  • For cuticle: Test freeze-crack, collagenase treatment, or reduction-oxidation

  • For internal tissues: Optimize detergent concentration and exposure time

  • Balance permeabilization with epitope preservation

• Blocking optimization:

  • Test tissue-specific autofluorescence quenching methods

  • Optimize blocking agents to minimize background

  • Include tissue-specific blocking components (e.g., acetylated BSA for nervous tissue)

• Signal amplification considerations:

  • For low-abundance expression: Consider tyramide signal amplification

  • For multi-labeling: Use appropriate fluorophore combinations

  • For thick tissues: Optimize clearing methods

These methodological considerations address tissue-specific challenges encountered in C. elegans immunostaining, building upon approaches used in developmental and protein localization studies .